Edison Issues Report on MindMaze Therapeutics (MMTX)

London, United Kingdom--(Newsfile Corp. - April 7, 2026) - Edison issues report on MindMaze Therapeutics (SIX: MMTX).

MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum of care from acute treatment to at-home recovery, providing differentiation and helping to avert treatment gaps. With US FDA and CE/MDR registrations and a unique US CPT Category III (CAT III) reimbursement for home-based therapy, MindMaze is primed for commercial roll-out across the US and Europe.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website:

www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291443

You May Also Be Interested In

• Galloper Gold Signs Strategic Partnership with Tier One Capital Corporation
• Boeing 737 Max 7 nears FAA certification after years of delays - WSJ
• The First AEO-Certified PR Agency Trustpoint Xposure Targets New York Law Firms, Guaranteeing Attorneys Appear in AI-Generated Legal Recommendations Before Competitors Claim the Position